Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 819-558-9
CAS number: 2020359-04-8
predicted data indicated that:(1)the compound could be absorbed
in small intestinewith a low absorption rate,(2)it may pass the
BBB easily,(3)it may have a moderate oral bioavailability between
30% and 70%,(4)it could bind with plasma proteins with a high
binding ratio of 98%,(5)it might be an inhibitor of P-gp, and(6)it
would not be an inhibitor of CYP450 and could be metabolized into
hydroxyl metabolites. The DS/ADMET calculated data suggested:(1)the
compound could pass the BBB;(2)it could be absorbed in small
intestine;(3)it would not be an inhibitor of CYP450 2D6;(4)its
binding ratio on plasma protein would be more than 95%.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again